Clinical trials: Liver Inflammation
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in participants with chronic HCV infection who were coinfected with HIV-1.
- Trial name
- ASTRAL-5 (NCT02480712)
- Testing
- SOF/VEL
- Where
- 15 sites in United States
- Volunteers
- 107 people
- Sponsor
- Gilead Sciences
Hepatitis C, Cryoglobulinemia
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
10 patients with chronic genotype 1 HCV infection and mixed cryoglobulinemia will be treated with Ledipasvir/Sofosbuvir 90mg/400 mg FDC once daily for 12 weeks (naïve subjects or non-cirrhotic treatment experienced subjects) or…
- Trial name
- NCT02825212
- Testing
- Harvoni, Epclusa
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatitis C, Chronic
Multidisciplinary Support Program in Chronic Hepatitis C
Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to achieve sustained virological response (SVR).
- Trial name
- NCT01850745
- Testing
- Multidisciplinary support program
- Where
- Spain
- Volunteers
- 447 people
- Sponsor
- Parc de Salut Mar
Hepatorenal Syndrome
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.
- Trial name
- NCT01143246
- Testing
- Terlipressin
- Where
- 73 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Mallinckrodt
Chronic Hepatitis c
Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)
Chronic hepatitis C has become an endemic disease in Egypt with a rising prevalence (genotype 4), worldwide it also poses a significant health burden.
- Trial name
- NCT01276756
- Testing
- Pegylated interferon alfa-2a, Nitazoxanide, Ribavirin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Hepatitis C, Chronic
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up…
- Trial name
- NCT02761629
- Testing
- Peg-Interferon Alpha-2A, Ribavirin
- Where
- 17 sites in Brazil
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
This Phase 4 study is designed for the collection of blood biomarker samples from participants who have completed CHB treatment with at least 24 weeks of a pegylated interferon alfa-2a (Peg-IFN alfa-2a) containing regimen and at…
- Trial name
- NCT01855997
- Testing
- Peg-IFN alfa-2a
- Where
- 84 sites in Austria, Bulgaria and 13 more
- Volunteers
- 1,669 people
- Sponsor
- Hoffmann-La Roche
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma
- Trial name
- NCT02940496
- Testing
- Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatitis C, Chronic
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
Follow-up for viral activity, changes in liver function and safety in patients with no SVR24 in feeder studies
- Trial name
- NCT02465203
- Testing
- Previous treatment in DEB025 study
- Where
- 40 sites in United States, Australia and 14 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic
A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)
This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) to participants with chronic hepatitis C virus (HCV) infection who did not achieve viral…
- Trial name
- NCT00943761
- Testing
- Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., Pegylated interferon
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B Virus Infection
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
To describe the immunogenicity and safety of modified process hepatitis B vaccine administered to renal predialysis and dialysis patients
- Trial name
- NCT00440297
- Testing
- Comparator: modified process hepatitis B vaccine, Comparator: ENGERIX-B™
- Volunteers
- 277 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hepatitis C
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not.
- Trial name
- NCT00728494
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908), Patient Assistance Program
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Hepatitis C
Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant
- Trial name
- REVERT (NCT00582738)
- Testing
- CsA-TAC (standard Treatment), Everolimus
- Where
- Argentina
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.
- Trial name
- NCT02738008
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 6 sites in China, Germany and 1 more
- Volunteers
- 12 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis C Virus Infection
Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
The primary objectives of this study are to determine the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks in participants with…
- Trial name
- NCT03118843
- Testing
- SOF/VEL/VOX
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic Disease
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
The purpose of this study is to evaluate antiviral activity and efficacy of entecavir (ETV) compared to adefovir in adults with chronic hepatitis B who have not been treated yet with an antiviral medicine.
- Trial name
- NCT00096785
- Testing
- entecavir, adefovir
- Where
- 24 sites in United States, Canada and 6 more
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
Open-label, extension study to evaluate the safety and efficacy of combination therapy and its effect on sustained viral response biomarkers.
- Trial name
- NCT03780543
- Testing
- standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 92 people
- Sponsor
- Assembly Biosciences
Hepatitis C
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) plus ribavirin (RBV) in Japanese participants with chronic genotype 2 hepatitis C virus (HCV) infection.
- Trial name
- NCT01910636
- Testing
- Sofosbuvir, RBV
- Where
- 19 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
Background: Chronic hepatitis B is caused by a virus that infects the liver. Cure is not possible but the virus can be controlled with the use of antiviral medicines,.
- Trial name
- NCT02364336
- Testing
- Peginterferon alfa-2a
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis A
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule
The aim of this study is to evaluate the persistence of hepatitis A antibodies at 138, 150, 162, 174,186, 198, 210, 222, 234 and 246 months after subjects received their first dose of a 2 dose vaccination schedule of hepatitis A…
- Trial name
- NCT00291876
- Testing
- Havrix™
- Where
- Belgium
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.